


To achieve capital growth and income from a portfolio of predominantly UK equities
| Name | % Net Assets |
|---|---|
| Royal Dutch Shell PLC | 8.7% |
| GlaxoSmithKline PLC | 6.3% |
| Vodafone Group PLC | 5.9% |
| BG Group PLC | 4.4% |
| AstraZeneca PLC | 4.4% |
| British American Tobacco PLC | 4.0% |
| Unilever PLC | 3.1% |
| Cadbury PLC | 2.8% |
| BP PLC | 2.8% |
| Centrica PLC | 2.7% |
| Key | % Net Assets |
|---|---|
| 8.7% | |
| 6.3% | |
| 5.9% | |
| 4.4% | |
| 74.7% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 987.76p |
| Currency | GBP |
| Change | 0.63p |
| % | 0.06% |
| YTD change | 112.29p |
| YTD % | 12.83% |
| Fund Inception | 01/05/1985 |
|---|---|
| Fund Manager | Christopher Metcalfe |
| TER | 1.61 (30-Dec-2011) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.06 |
You are here: research